Ming‐Tsung Lin

A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial

Wei‐Chen Tai, Chih‐Ming Liang, Chung‐Mou Kuo et al. · Journal of Antimicrobial Chemotherapy · 2019 · 94 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience

Ming‐Chao Tsai, Chia‐Hsiang Chen, Po‐Lin Tseng et al. · Clinical Microbiology and Infection · 2015 · 61 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

Kuo‐Chin Chang, Po‐Lin Tseng, Yi‐Ying Wu et al. · Clinical Gastroenterology and Hepatology · 2014 · 55 citations

Medicine, Immunology, Infectious Diseases +17

Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease

Yi‐Hao Yen, Kuo‐Chin Chang, Ming‐Chao Tsai et al. · Journal of the Formosan Medical Association · 2017 · 40 citations · Full text

Medicine, Internal Medicine, Pathology +17

Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts

Po‐Lin Tseng, Te‐Chuan Chen, Yu-Shu Chien et al. · American Journal of Kidney Diseases · 2013 · 29 citations

Medicine, Nephrology, Pharmacotherapy +12